At the small-animal clinic level, compressed oral tablets containing diphenhydramine hydrochloride for canine allergic dermatitis, acute urticaria, and motion sickness prophylaxis are produced as immediate-release cores in 25 mg and 50 mg strengths. The API addition ratio is calculated on the finished core weight: a 25 mg dose in a 200 mg core represents 12.5% w/w, while a 50 mg dose in a 250 mg core represents 20.0% w/w. Direct compression is viable when the API fraction remains at or below 20% w/w; beyond that, the acicular crystal habit of diphenhydramine hydrochloride increases die-filling variability and produces capping in rotary presses. Wet granulation with 5% w/w povidone K30 binder solution is therefore used for the 50 mg strength. A 1,000 L bin blender is used for initial dry mixing at 12 rpm for 20 minutes; granulation proceeds through a 1.0 mm mesh, followed by fluid-bed drying at 50–60°C inlet air until loss on drying falls below 2.0%. Lubrication with 0.5%–1.0% w/w magnesium stearate for 2–5 minutes precedes compression on a 45-station rotary tablet press at 60,000–120,000 tablets/h. Finished cores are tested against USP <905> uniformity of dosage units, USP <701> disintegration with a 30-minute limit, and USP <711> dissolution using Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid. Manufacture is controlled under 21 CFR 211.110 and 211.165, with residual solvents per USP <467> and elemental impurities per ICH Q3D. Terminal product types are 25 mg and 50 mg scored tablets in 100-count and 500-count HDPE bottles with desiccant canisters, and palatable chewable tablets containing 25 mg API in a compressible sugar-starch base with hydrolyzed poultry liver or porcine liver powder as flavoring.

For direct compression, the API and microcrystalline cellulose are passed through a 0.8 mm screen and conditioned at 20–25°C and 35–45% RH before processing. D2 tool steel punch faces are used, and the score line is validated for half-dose splitting accuracy after compression. When ambient relative humidity exceeds 60%, lactose monohydrate is pre-dried at 40°C for 2 h before final blending to prevent punch filming and mass-flow obstruction in the feed frame.

When Is a 50 mg/mL Sterile Injectable Preferred Over Oral Dosage in Acute Equine or Canine Allergic Reactions?

In acute equine and canine allergic responses where intravenous access is available, parenteral diphenhydramine hydrochloride is formulated as a sterile aqueous solution at 50 mg/mL, equivalent to 5.0% w/v. The solution is prepared by dissolving the API in water for injection at 20–25°C, adjusting pH to 4.5–6.0 with 1 N sodium hydroxide or hydrochloric acid, and, for multidose vials, adding benzyl alcohol at 1.0%–1.5% v/v as preservative. The bulk solution is filtered through 0.22 µm PVDF membranes and filled into Type I glass vials under Grade A laminar airflow. Terminal moist-heat sterilization at 121°C for 15 minutes is applied to preservative-containing multidose vials when solution pH is held within the validated zone; single-dose vials are processed by aseptic filtration when terminal sterilization is not assigned. Release testing includes USP <1> Injections, USP <85> bacterial endotoxins with an acceptance criterion of not more than 0.5 EU/mg, USP <788> particulate matter for subvisible particles, and USP <790> visible particulate inspection. Sterile manufacturing follows 21 CFR 211.113 and 211.167. Terminal product types are 10 mL single-dose vials and 50 mL multidose vials for slow intravenous or intramuscular administration in horses and dogs; the formulation is not established for food-producing species, and extra-label administration to cattle, swine, or small ruminants is restricted under 21 CFR 530.41 because no validated edible-tissue withdrawal period has been assigned. Published stability data for all preservative and container configurations is limited, so forced-degradation studies under ICH Q1B are required for any new registrant to define photostability and pH drift before filing.

The bulk solution is sparged with nitrogen to maintain dissolved oxygen below 1.0 mg/L and filled under nitrogen overlay to reduce oxidative degradation. Terminal sterilization cycles are designed to deliver an F0 value not less than 12 minutes; for aseptic filtration, the formulation is passed through a 0.45 µm prefilter followed by a 0.22 µm PVDF membrane. Transmembrane pressure is maintained below 2.0 bar to avoid filter shedding.

For feline patients requiring a liquid dosage form, oral solutions are compounded from diphenhydramine hydrochloride powder to prepare 2 mg/mL and 5 mg/mL liquids, corresponding to 0.2% w/v and 0.5% w/v API. The vehicle consists of purified water, 0.5% w/v hydroxyethylcellulose as a viscosity modifier, saccharin sodium or sucralose as bitterness suppressant, and a phosphate-citrate buffer to hold pH at 4.0–5.5. The pH range is selected because diphenhydramine hydrochloride remains protonated and water-soluble under these conditions, and oxidative discoloration is slowed relative to neutral or alkaline vehicles. Compounding is performed by levigating the API with glycerin or propylene glycol, then incorporating the slurry into the vehicle with high-shear mixing at 3,000 rpm for 10 minutes. The resulting liquid is packaged in amber glass or PETE bottles fitted with oral syringe adapters. Since no FDA-approved feline diphenhydramine oral solution is marketed in many regions, the preparation is an extra-label use under 21 CFR 530, and routine feline administration is not subject to food residue testing. Nonsterile compounding standards under USP <795> apply, with a default beyond-use date of 14 days refrigerated unless a stability-indicating HPLC assay supports extension. Potency retention at release is specified as 90.0%–110.0% of label claim. Terminal finished product types are 30 mL and 60 mL oral syrup bottles supplied with 1 mL dosing syringes calibrated in 0.1 mL increments.

Where Hard Capsule Blending Without Prior Granulation Becomes Feasible for Canine Motion Sickness Protocols

In low-dose capsule filling, diphenhydramine hydrochloride is filled into hard gelatin or HPMC capsules in 25 mg and 50 mg strengths for adjunctive management of canine motion sickness and mild sedation. The addition ratio is limited by the capsule fill weight and the poor flow of unmilled API: a size 3 capsule receiving 25 mg API with 120 mg lactose monohydrate and 2 mg magnesium stearate yields 17.0% w/w, while a 50 mg strength at 160 mg total fill mass yields 31.3% w/w. Direct filling is restricted to the 25 mg strength; at API fractions above 25% w/w, the acicular particles bridge in the feed hopper and produce fill-weight RSD outside ±3%. Blending is performed in a 300 L IBC bin blender at 10 rpm for 15 minutes, followed by lubrication with 0.5% w/w magnesium stearate for 3 minutes. An intermittent-motion capsule filler operating at 30,000–60,000 capsules/h is used with tamping pins adjusted to produce plug densities of 0.65–0.75 g/mL; 100% checkweighing removes units outside ±3% of target fill mass. Capsules are tested for dissolution under USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid, content uniformity under USP <905>, and moisture content by Karl Fischer titration at not more than 4.0% for gelatin shells. Manufacturing operations comply with 21 CFR 211.110 and 211.165. Terminal product types are size 3 hard gelatin capsules in 30-count and 100-count blister strips and HDPE bottles with desiccant canisters.

Equine Oral Granule and Powder Handling Limits for Compounded Antihistamine Therapy

Because the hydrochloride salt exhibits an intense bitter taste that depresses voluntary equine consumption, granulated powders for equine oral administration are prepared as 100 mg/g diphenhydramine hydrochloride granules, equivalent to 10% w/w API, with lactose monohydrate and pregelatinized starch as fillers and povidone K30 as the granulating binder. A 10 g sachet delivers 1,000 mg API, which is diluted in water or mixed into a small amount of feed immediately before administration; free-choice dry top-dressing is unreliable. Wet granulation is performed in a high-shear mixer at impeller 400 rpm and chopper 2,500 rpm, with purified water added to 8%–12% w/w of dry blend mass. The wet mass is extruded through a 1.25 mm screen, dried in a fluid-bed dryer at 45–55°C to 1.5%–2.5% final moisture, and sieved between 180 µm and 1.25 mm. Fines below 180 µm are recycled at not more than 20% of batch mass to avoid over-lubrication and content non-uniformity in the sachet fill. Compounded equine powders are governed by USP <795>; without a stability study, the beyond-use date should not exceed 30 days at 20–25°C or 90 days refrigerated. Commercial approval of an equine granule would require 21 CFR 211 compliance, ICH Q3D elemental impurity control, and container closure integrity per USP <671>. Terminal product forms are 10 g and 25 g foil-laminate sachets, 500 g HDPE jars with measuring scoops, and unit-dose pre-weighed powders for reconstitution before nasogastric administration.

A Nonsterile Premix Serves as a Dose-Controlled Intermediate for Veterinary Pharmacy Compounding

For compounding pharmacies that prepare multiple low-dose oral forms, diphenhydramine hydrochloride premixes are manufactured as 50% w/w API triturations in lactose monohydrate carrier to improve weighing accuracy and uniformity in subsequent capsule, oral liquid, and powder preparations. The 50% trituration reduces the minimum weighable quantity for a 25 mg capsule to 50 mg total premix, approximately 10 times above the repeatability limit of a 0.1 mg analytical balance. Production uses geometric dilution in a low-shear V-blender, with the API pre-sieved through a 250 µm mesh to break agglomerates before blending at 15 rpm for 20 minutes. Blend uniformity is evaluated by HPLC at five sampling points; each point must assay between 90.0% and 110.0% of label claim, with an RSD not more than 5.0%. Under USP <795>, the premix is a nonsterile compounded preparation, and a beyond-use date of 180 days can be assigned only when a stability-indicating assay and container-closure evaluation support it. The source diphenhydramine hydrochloride must be accompanied by a certificate of analysis meeting a veterinary or USP monograph, including residual solvents per USP <467> and elemental impurities per ICH Q3D. Terminal product types are 100 g and 500 g amber HDPE jars with child-resistant closures, labeled “For Prescription Compounding Only—Not for Retail Sale” and intended exclusively for pharmacy preparation of capsules, oral liquids, and unit-dose powders.